Oral vinorelbin in combination with cisplatin or carboplatin in adjutant chemotherapy of non-snall lung cancer: A prospective study of feasibility, tolerabity an 3-year surfoval
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00052780" target="_blank" >RIV/00216224:14110/11:00052780 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Oral vinorelbin in combination with cisplatin or carboplatin in adjutant chemotherapy of non-snall lung cancer: A prospective study of feasibility, tolerabity an 3-year surfoval
Original language description
Adjuvant cisplatinum-based chemotherapy is recommended for routine use in patients with stages IIA, IIB, and IIIA of non smallcell lung cancer (NSCLC) after radical resection. Results in stage IB were not conclusive. Vinorelbine is a preferable associated drug in this indication and a randomized study proved the comparable effectiveness and tolerability of vinorelbine given both orally or intravenously (i.v.) in advanced NSCLC, meanwhile oral vinorelbine gives better comfort to patients.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů